Get the Stockscreener App
2.07
5.91%
-0.13
After Hours:
2.06
-0.010
-0.48%
Nrx Pharmaceuticals Inc stock is traded at $2.07, with a volume of 586.23K.
It is down -5.91% in the last 24 hours and down -21.59% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.20
Open:
$2.19
24h Volume:
586.23K
Relative Volume:
1.32
Market Cap:
$58.16M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.5175
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-12.29%
1M Performance:
-21.59%
6M Performance:
-39.83%
1Y Performance:
+72.50%
1-Day Range:
$2.06
$2.2378
1-Week Range:
$2.06
$2.39
52-Week Range:
$1.17
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.07 | 61.81M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Market Outlook: Does NRx Pharmaceuticals Inc stock trade at a discount to peersJuly 2025 Drop Watch & Stock Timing and Entry Methods - moha.gov.vn
NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment - MyChesCo
NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Cash from financing activities of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView
Is NRx Pharmaceuticals Inc. stock a bargain at current levelsMarket Rally & Weekly Top Stock Performers List - Newser
BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals amends IND filing for NRX-101 to include use for TMS - MSN
Is NRx Pharmaceuticals Inc. Equity Warrant stock cheap compared to fundamentalsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus
NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - NewMediaWire
NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - Digital Journal
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail
NRx Pharmaceuticals to Discuss New NRX-101 Pipeline Indication for Augmentation of Transcranial Magnetic Stimulation - citybiz
Nrx Pharmaceuticals Inc amends IND filing for NRX-101 to include TMS use - marketscreener.com
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation - Investing News Network
NRx Pharmaceuticals Amends Investigational New Drug Filing for NRX-101 to Include Use with Transcranial Magnetic Stimulation in Treatment of Depression - Quiver Quantitative
BTIG Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial ... - Enidnews.com
NRx Pharmaceuticals to discuss new NRX-101 pipeline - GlobeNewswire
D. Boral Capital Maintains NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
Market Wrap: What momentum indicators show for NRx Pharmaceuticals Inc. stock2025 Valuation Update & Precise Trade Entry Recommendations - BỘ NỘI VỤ
NRx Pharmaceuticals (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - Digital Journal
NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - NewMediaWire
NRXP: Analyst Maintains 'Buy' Rating with $34 Target Price | NRX - GuruFocus
FDA Submission for Abbreviated New Drug Application; $750 - openPR.com
NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV KetamineNRx Pharmaceuticals - citybiz
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine - The Manila Times
Nrx Pharmaceuticals announces US Food and Drug Administration (FDA) receipt of ANDA for Ketafree - marketscreener.com
Nrx Pharmaceuticals Announces Us Food And Drug Administration (FDA) Receipt Of ANDA For Ketafree - TradingView
NRx Pharmaceuticals Announces US Food and Drug - GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call - The Manila Times
NRx Pharmaceuticals (NASDAQ: NRXP) plans Dec. 2, 9:00am ET corporate update call - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at NobleCon21 - MSN
NRx Pharmaceuticals (NRXP) to Present at NobleCon21 - NewMediaWire
NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - citybiz
NRx Pharmaceuticals to Present at NobleCon21 on Advances in Psychiatric Treatments and Drug Development - Quiver Quantitative
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference - marketscreener.com
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to - GlobeNewswire
What Macro Trends Could Affect Ruchira Papers Limiteds OutlookStock Valuation Metrics & Free Discover Breakout Stocks Early - earlytimes.in
Is NRx Pharmaceuticals Inc. stock a buy in volatile marketsMarket Activity Summary & Reliable Price Breakout Alerts - BỘ NỘI VỤ
NRx Pushes Fast-Track Depression Treatments as Losses Mount and Clinics Expand - MSN
Why NRx Pharmaceuticals Inc. Equity Warrant stock attracts global investorsWeekly Trade Report & Expert Curated Trade Setup Alerts - moha.gov.vn
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA) (PR Newswire) - Aktiellt
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products (PR Newswire) - Aktiellt
NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg By Investing.com - Investing.com Canada
NRx Pharmaceuticals appoints Weinberg as new auditor, dismisses Salberg - Investing.com
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):